The Inflammatory Burden in Hemodialysis vs. Peritoneal Dialysis Patients: the Role of Alpha-defensin

Not Applicable

• Conditions: Kidney Failure; Inflammation
• Interventions: Diagnostic Test: Blood Test

• Registration Number: NCT03845530
• Lead Sponsor: Hillel Yaffe Medical Center

Brief Summary

The aim of this study is to determine the levels of alpha-defensin throughout the hemodialysis course compared to the levels at the end of a course of peritoneal dialysis, as a reflection of the inflammatory burden.

Detailed Description

Not available

Study Timeline

• Status Verified: 2019-02
• Study First Submitted: 2019-02-18
• Study First Submitted QC: 2019-02-18
• Last Update Submitted: 2019-02-18
• Study First Posted: 2019-02-19
• Last Update Posted: 2019-02-19
• Study Start: 2019-03
• Primary Completion: 2020-03
• Study Completion: 2020-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Kidney failure patients undergoing hemodialysis or peritoneal dialysis

Exclusion Criteria

• Active inflammatory or infectious disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Peritoneal dialysis	Blood Test	Blood sample taken and sent to laboratory for analysis
Hemodialysis group	Blood Test	Blood sample taken and sent to laboratory for analysis

Primary Outcome Measures

Name	Time	Method
Alpha-Defensin Levels	One year	Alpha-defensin levels will be compared between the two arms

Trial Locations

Locations (1)

Hillel Yaffe Medical Center; 🇮🇱 Hadera, Israel